Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study

Overview of attention for article published in Breast Cancer Research and Treatment, September 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (90th percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news: 1 news outlet
policy: 1 policy source
twitter: 8 X users

patent: 2 patents
f1000: 1 research highlight platform

Citations

dimensions_citation: 79 Dimensions

Readers on

mendeley: 97 Mendeley

Summary News Policy documents X Patents Research highlights Dimensions citations

So far, Altmetric has seen 1 news story.

Commentary: Evaluating first-line regimens in breast cancer, March 2023 (of 11)

Pediatric News , 01 Mar 2023

The KEYNOTE-522 study has established a regimen of carboplatin/paclitaxel/pembrolizumab followed by doxorubicin/cyclophosphamide…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.